Examining the NCCN Recommendations for Genetic Testing in Prostate Cancer

Levo Therapeutics Announces FDA Fast Track Designation for Intranasal Carbetocin in Treating Prader-Willi syndrome

A key recommendation from the 2019 National
Comprehensive Cancer Network (NCCN) involves its guidelines on genetic testing
and counseling in prostate cancer, in that men with high-risk, extreme
high-risk, regional, or metastatic disease should receive genetic testing and
counseling. The guidelines also provide more in-depth information
regarding family history, making it more clear what history to collect and how
to use the information. By understanding this additional background information, oncologists
may be able to determine the number of genes that should be assayed for
mutations, which may ultimately improve treatment outcomes.

Earlier this year, the NCCN Prostate Cancer
Panel reported updated guidelines for genetic testing in prostate cancer during
the NCCN Annual Meeting, held March 21 through March 23 in Orlando, Florida.
The guidelines highlight a 2016 study evaluating inherited DNA-repair gene
mutations in men with metastatic prostate cancer. The
results showed no difference in mutation frequency among patients with a family
history of prostate cancer and those without. Additionally, men with metastatic
disease had a significantly higher frequency of germline mu...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee